Liver transplant patients may cut lifelong drugs with simple ultrasound test
NCT ID NCT07206277
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special ultrasound called a fibroscan can help doctors safely lower the dose of anti-rejection drugs in liver transplant recipients. Participants must be at least 2 years post-transplant, have normal liver blood tests, and not have autoimmune liver disease or recent rejection. The goal is to reduce drug doses by 30% without causing rejection, which could lower side effects like kidney problems, diabetes, and cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNOSUPPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G2R3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••